Premium
Diabetes as a result of atypical anti‐psychotic drugs – a report of three cases
Author(s) -
Rigalleau V.,
Gatta B.,
Bonnaud S.,
Masson M.,
Bourgeois M. L.,
Vergnot V.,
Gin H.
Publication year - 2000
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1046/j.1464-5491.2000.00296.x
Subject(s) - medicine , diabetic ketoacidosis , diabetes mellitus , ketoacidosis , insulin , olanzapine , clozapine , ketosis , pediatrics , weight loss , schizophrenia (object oriented programming) , psychosis , endocrinology , type 1 diabetes , psychiatry , obesity
Summary Aims Atypical anti‐psychotic drugs (APDs) are widely used in psychotic disorders refractory to conventional neuroleptic agents. Results Three cases of new‐onset diabetes are reported in Caucasian men who were on clozapine (one) or olanzapine (two) for 3–6 months. They had a distinct presentation: weight loss, ketosis (one ketoacidosis), severe hyperglycaemia requiring insulin therapy, and relative insulin deficiency as reflected by glucagon stimulatory tests. In all cases, insulin was stopped within 1 month after the APD was discontinued. Conclusions Novel APDs not only induce diabetes as a result of weight gain in predisposed patients, but can also lead to a reversible state of insulin deficiency, and sometimes ketoacidosis.